Expert doctors in infectious disease and lung health speak to the transmissibility of walking pneumonia and more infection ...

Preventive vaccination is essential in reducing the severity of symptoms and limiting the spread of infectious diseases, especially as flu season approaches, according to medical experts from the ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

Recent findings of the impact of new RSV prevention products aimed at protecting babies were published in the Morbidity and Mortality Weekly Report, an epidemiological digest prepared by the Centers ...

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.